Tetraphase Pharmaceuticals is a clinical-stage life science company with a synthetic chemistry technology platform that has the power to address the global health crisis caused by antibiotic resistance. Since the company’s inception in late 2006, Tetraphase has developed a robust antibiotics platform based on the tetracycline core, which offers the potential to dramatically improve the treatment of both broad and selective spectrum bacterial infections.
Tetracyclines are proven antibacterial agents and represent one of the most trusted classes of antibiotics. To date, all commercial tetracycline antibiotics have been prepared by fermentation-semisynthesis, which is an inherently limited process. Tetraphase’s fully synthetic approach provides new avenues for the discovery and development of novel and potent antibiotics with unique profiles. Tetraphase has leveraged this powerful new approach, which was pioneered at Harvard, to produce a pipeline of novel tetracycline antibiotics.
Tetraphase is rapidly advancing its clinical pipeline of potent novel antibiotics. In terms of spectrum, potency, efficacy, safety and dosing convenience/flexibility, Tetraphase’s pipeline offers significant differentiation from currently marketed products for the treatment of serious infections as well as from those in development by other companies.